- Open
- 9.75
- High
- 10.00
- Low
- 9.50
- Close
- 10.00
- Change
- -0.25 (-2.56%)
- Volume
- 454,281
| 20 Jul 2026 | 09:00:00 | Grant of options |
| 1 Jul 2026 | 16:45:25 | Holding(s) in Company |
| 30 Jun 2026 | 17:00:00 | Total Voting Rights |
| 22 Jun 2026 | 07:00:11 | Notice of allowance of patent in Canada |
| 15 Jun 2026 | 07:00:12 | Update on grant-funded DR5 project |
| 17 Sep 2024 | Annual Report and Accounts (to 2024-03-31) | |
| 10 Oct 2023 | Annual Report and Accounts (to 2023-03-31) | |
| 28 Sep 2022 | Annual Report and Accounts (to 2022-03-31) |
Fusion Antibodies plc is a Contract Research Organisation (CRO) based in Northern Ireland that specializes in antibody discovery, engineering, and expression services for therapeutic and diagnostic applications. The company provides a comprehensive range of services, including the identification and optimization of antibodies, as well as the production of high-quality antibodies and cGMP-ready manufacturing cell lines. Fusion serves customers in the biopharmaceutical, veterinary, diagnostic, and life sciences sectors, focusing on both human and veterinary therapeutic markets. Its operations extend into various global markets, leveraging advanced technologies to enhance antibody performance and supply continuity.
| 20 Jul 2026 | 09:00:00 | Grant of options |
| 1 Jul 2026 | 16:45:25 | Holding(s) in Company |
| 30 Jun 2026 | 17:00:00 | Total Voting Rights |
| 22 Jun 2026 | 07:00:11 | Notice of allowance of patent in Canada |
| 15 Jun 2026 | 07:00:12 | Update on grant-funded DR5 project |
| 17 Sep 2024 | Annual Report and Accounts (to 2024-03-31) | |
| 10 Oct 2023 | Annual Report and Accounts (to 2023-03-31) | |
| 28 Sep 2022 | Annual Report and Accounts (to 2022-03-31) |
Fusion Antibodies plc is a Contract Research Organisation (CRO) based in Northern Ireland that specializes in antibody discovery, engineering, and expression services for therapeutic and diagnostic applications. The company provides a comprehensive range of services, including the identification and optimization of antibodies, as well as the production of high-quality antibodies and cGMP-ready manufacturing cell lines. Fusion serves customers in the biopharmaceutical, veterinary, diagnostic, and life sciences sectors, focusing on both human and veterinary therapeutic markets. Its operations extend into various global markets, leveraging advanced technologies to enhance antibody performance and supply continuity.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £123m | +0.0% | |
FABFusion Antibodies PLC | £13m | -0.1% |
| £12m | +0.5% | |
| £10m | -0.1% | |
| £10m | +0.4% | |
| £5m | -0.5% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £123m | +0.0% | |
FABFusion Antibodies PLC | £13m | -0.1% |
| £12m | +0.5% | |
| £10m | -0.1% | |
| £10m | +0.4% | |
| £5m | -0.5% |
